C
ombination antiretroviral therapy (cART) has revolutionized HIV care over the past 15 years, converting a fatal disease into a treatable chronic condition. Despite this success, uncertainty remains regarding the optimal time to initiate cART. In 1998, the U.S. Department of Health and Human Services recommended an aggressive approach of starting cART at any CD4 cell count less than 0.500 ϫ 10 9 cells/L (1). Concerns about drug toxicity and accumulating resistance mutations motivated the panel to subsequently lower the CD4 cell count threshold to 0.200 to 0.350 ϫ 10 9 cells/L. Because of the improved short-term safety of currently regimens and the appreciation that HIV infection may contribute to non-AIDS-related conditions, the 2011 U.S. Department of Health and Human Services guidelines again recommend that cART be initiated at CD4 cell counts of 0.500 ϫ 10 9 cells/L or less and be considered at CD4 cell counts greater than 0.500 ϫ 10 9 cells/L. Although only 50% of the panel supported the latter recommendation (2), use of this threshold would effectively mean offering treatment to everyone with diagnosed HIV infection.
The study by the HIV-CAUSAL Collaboration in this issue (3) is the third recently published comprehensive cohort analysis to address the question of when to start cART (4, 5) . This analysis reported increased mortality only when cART initiation was deferred until CD4 cell counts decreased to less than 0.200 ϫ 10 9 cells/L. However, a benefit was seen for starting cART at CD4 cell counts above 0.500 ϫ 10 9 cells/L by using a broader end point that included nonfatal AIDS-related events, with the notable caveat that such events (for example, esophageal candidiasis) are typically less severe at higher CD4 cell counts. The When to Start Consortium previously reported increased risk for AIDS or death when cART initiation was deferred until CD4 counts decreased to less than 0.350 ϫ 10 9 cells/L, whereas mortality risk was greater only when thresholds approached 0.200 ϫ 10 9 cells/L (4). In contrast, analyses by the NA-ACCORD (North American AIDS Cohort Collaboration on Research and Design) reported a striking 94% increased risk for death when cART was deferred until CD4 counts decreased to less than 0.500 ϫ 10 9 cells/L, even without including nonfatal AIDSrelated events (5) . Finally, recently presented data from the CASCADE (Concerted Action on SeroConversion to AIDS and Death in Europe) Collaboration (6) also found a persistent, but diminishing, reduction in risk for AIDS or death with earlier cART initiation, but the number needed to treat to show benefit above the threshold of 0.500 ϫ 10 9 cells/L was infinity. The differing results from these cohort studies may, in part, reflect differences in the statistical methods used.
An important limitation of the cohort data in these trials is the lack of outcomes related to serious, nonfatal, non-AIDS-defining conditions, which are the most common causes of morbidity and mortality at higher CD4 cell counts (7) . A widely held hypothesis is that persistent HIV-related inflammation may contribute to premature development of non-AIDS-related events, such as cardiovascular disease, and that earlier use of cART (with HIV suppression) would attenuate this risk. An important caveat is that a disproportionate amount of HIV-related damage to the immune system occurs very soon after initial infection (8) , so even early cART initiation (for example, at CD4 cell counts Ͼ0.500 ϫ 10 9 cells/L) may be too late to reverse the process. In addition, cART seems to only partially attenuate inflammation while potentially increasing toxicity (9, 10) . Although risk for non-AIDS-related events has been inversely associated with CD4 cell counts (11), the pathogenesis for these events is currently not wellunderstood and probably differs by disease.
The other critical limitation inherent in all cohort studies is unmeasured confounding, which can contribute to clinical decisions to start or defer cART in any given patient. This type of bias may have contributed to the large differences in mortality risk between the HIV-CAUSAL and NA-ACCORD results, and can only be addressed by a randomized trial. Investigators in the ongoing START (Strategic Timing of Anti-Retroviral Therapy) randomized trial seek to characterize the benefits (related to both AIDS-related and non-AIDS-related events) of starting cART at a CD4 cell count greater than 0.500 ϫ 10 (Figure) . The potential for a modest benefit from starting cART in all patients must be weighed against the long-term toxicity and the cost of therapy, both for the patient and society.
To this end, a key aspect of efforts to expand cART use is the societal benefit from reduced transmission. The use of broad HIV testing and early treatment leads to the concept of community viral load, in which the public health goal of decreasing HIV transmission is achieved by minimizing the number of persons in a community with a detectable viral load. Studies of HIV-serodiscordant cou-
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Editorial ples have consistently demonstrated that a lower viral load is associated with lower transmission risk (12). Examples of a similar effect of reduced HIV incidence with decreases in the community viral load are being reported (13, 14) . Of note, rates of HIV infection remain significant in San Francisco and Vancouver, possibly because of undiagnosed infections. Up to 50% of new HIV infections may originate from persons who are themselves recently infected (15) , and this seems supports the argument for aggressive early treatment. However, the diagnosis of HIV infection is typically missed in most recently infected persons. Questions remain about whether the reduced HIV incidence from expanded cART use can be sustained over decades, and whether compensatory changes in risk behavior will attenuate or undermine this benefit (for example, syphilis rates are increasing in communities that reported recent decreases in HIV incidence) (16, 17) .
Encouraging results from clinical studies, modeling studies, real-world observations, and public health reporting have led to a sense that the HIV epidemic can be controlled by expanding the indications for cART. Unfortunately, in the current fiscal reality, the "test and treat everyone" strategy seems to require more resources than are available. Despite the impressive gains from wider cART access in many resource-poor areas, program expansion (and maintenance) is threatened by current projections for HIV funding. Funding for the President's Emergency Program for AIDS Relief has leveled off, and nearly 7000 HIV-positive patients in the United States were waiting to access cART through the AIDS Drug Assistance Program as of March 2011 (18). Federal and state discretionary budgets in the United States, including those directed at HIV care, propose severe cuts, and similar challenges will probably complicate HIV care throughout the world.
Rationing health care, in the form of access to services, already exists in the United States. In many states, access to cART is on a first-come, first-served basis for poor HIVinfected patients. In real terms, patients with newly diagnosed AIDS (who have a high mortality risk) wait to start cART in some areas in the United States because treatment was started earlier in the fiscal year for patients with high CD4 cell counts (when cART has less clinical benefit). The U.S. National HIV/AIDS Strategy (19) emphasizes increasing access to care, but treating HIV infection on a first-come, first-served basis may compromise that goal. Modeling the strategy of giving preference to patients with lower CD4 cell counts yields superior outcomes (20) , and this approach may need to be considered in many settings (Figure) .
Expanded use of cART could substantially curtail the future HIV epidemic. The HIV-CAUSAL Collaboration study is a robust, carefully performed analysis that supports the presence of a graded benefit of cART even when risk for AIDS is low, but uncertainty remains regarding the cumulative benefits, in absolute terms, of treating everyone with HIV infection. Investment in well-conceived clinical studies is often met with resistance because of the up-front costs, particularly in current times, but the continuing HIV epidemic and tightening resources requires that we clarify the absolute benefits, risks, and costs of expanding the indications for cART. Improved care for our patients with HIV infection in an era of fiscal constraint is a goal we can achieve, as long as we have sound data to inform both individual treatment and public policy decisions. A schematic interpretation of the benefits of initiating cART to reduce individual health risk on the basis of CD4 cell count. Initiating cART at higher versus lower CD4 cell count thresholds may result in a much smaller absolute benefit, as indicated by the slope of curve. A strategy of initiating cART earlier and at higher CD4 cell counts, with the ultimate goal of identifying and treating everyone, will eventually outpace available resources. cART ϭ combination antiretroviral therapy.
